An open label Phase 1B dose finding study of BI 836880 in combination with BI 754091 to characterise safety, tolerability, pharmacokinetics, pharmacodynamics and efficacy in patients with locally advanced or metastatic non-squamous non-small cell lung cancer and in other solid tumours.